Expertise in
38
conditions

Dr. Rajani P. Nadkarni

Hematology | Oncology
Hartford Healthcare Medical Group
435 Lewis Ave Ste 220, 
Meriden, CT 
Offers Telehealth
Expertise in
38
conditions
Hartford Healthcare Medical Group
435 Lewis Ave Ste 220, 
Meriden, CT 

Overview

Rajani Nadkarni is a Hematologist and an Oncologist practicing medicine in Meriden, Connecticut.

Dr. Nadkarni is highly rated in 38 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Angiosarcoma, Paget Disease of the Breast, and Inflammatory Breast Cancer.

She is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 3 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in CT

Hospital Affiliations

Hartford Hospital
Charlotte Hungerford Hospital
The Hospital Of Central Connecticut
Midstate Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Hartford Healthcare Medical Group
435 Lewis Ave Ste 220, Meriden, CT 06451

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Enrollment Status: Completed
Publish Date: February 19, 2026
Intervention Type: Drug
Study Drugs: Trastuzumab, Paclitaxel, Trastuzumab emtansine
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
View 2 Less Clinical Trials

3 Total Publications

The impact of cancer metastases on COVID-19 outcomes: A COVID-19 and Cancer Consortium registry-based retrospective cohort study.
The impact of cancer metastases on COVID-19 outcomes: A COVID-19 and Cancer Consortium registry-based retrospective cohort study.
Journal: Cancer
Published: June 26, 2023
Similar Doctors
Expertise in
11
conditions
Dr. Farzana D. Pashankar
Hematology | Oncology
Expertise in
11
conditions
Dr. Farzana D. Pashankar
Hematology | Oncology
Referral may be required

Yale New Haven Hospital

20 York St, 
New Haven, CT 
 (17.4 miles away)
203-785-4081
Languages Spoken:
English
See accepted insurances

Farzana Pashankar is a Hematologist and an Oncologist practicing medicine in New Haven, Connecticut. Dr. Pashankar is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Germ Cell Tumor, Teratoma of the Mediastinum, Testicular Yolk Sac Tumor, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
29
conditions
Dr. Philip C. Caron
Hematology | Oncology
Expertise in
29
conditions
Dr. Philip C. Caron
Hematology | Oncology
Referral may be required

Memorial Sloan Kettering Cancer Center Westchester

500 Westchester Ave, 
West Harrison, NY 
 (59.1 miles away)
332-334-8556
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Philip Caron is a Hematologist and an Oncologist practicing medicine in West Harrison, New York. Dr. Caron is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Follicular Lymphoma, and Diffuse Large B-Cell Lymphoma (DLBCL). Dr. Caron is currently accepting new patients.

Expertise in
65
conditions
Dr. Gerard Fumo
Hematology | Oncology
Expertise in
65
conditions
Dr. Gerard Fumo
Hematology | Oncology
Referral may be required

Hartford Healthcare Medical Group

435 Lewis Ave Ste 220, 
Meriden, CT 
 (0.1 miles away)
203-238-7747
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gerard Fumo is a Hematologist and an Oncologist practicing medicine in Meriden, Connecticut. Dr. Fumo is highly rated in 65 conditions, according to our data. His clinical expertise encompasses Familial Colorectal Cancer, Gastroesophageal Junction Cancer, Colorectal Cancer, and Thrombocytopenia.

Frequently Asked Questions about Dr. Rajani P. Nadkarni

How do I make an appointment with Dr. Rajani P. Nadkarni?

You can book an appointment with Dr. Rajani P. Nadkarni by calling their office at 203-238-7747. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rajani P. Nadkarni a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rajani P. Nadkarni is classified as an Distinguished expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rajani P. Nadkarni specialize in?

While Dr. Rajani P. Nadkarni is a Hematology, they have specific expertise in Non-Hodgkin Lymphoma, Angiosarcoma, and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Rajani P. Nadkarni participate in research or clinical trials?

Yes. Dr. Rajani P. Nadkarni has published 3 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Rajani P. Nadkarni's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rajani P. Nadkarni accept my insurance?

Dr. Rajani P. Nadkarni accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 203-238-7747 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nadkarni's expertise for a condition
ConditionClose
    View All 32 Advanced Conditions
    View All 107 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile